Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TMJ implants

This article was originally published in The Gray Sheet

Executive Summary

In a Jan. 21 letter to Commissioner David Kessler, Rep. Edolphus Towns (D-N.Y.) asks FDA to brief the staff of his House Government Operations/Human Resources Subcommittee "on or about" Feb. 11 "on all FDA activities associated with [temporomandibular joint] implants conducted since the subcommittee's hearing that was held on June 4, 1992 and on all current and planned FDA activities associated with TMJ implants." In October, subcommittee staffers said that followup of TMJ-related issues was a "top priority" for Towns ("The Gray Sheet" Oct. 18, In Brief). The panel's investigation focuses on health hazards associated with TMJ implants
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT001792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel